ID: ALA3143520

Max Phase: Preclinical

Molecular Formula: C31H43N5O5

Molecular Weight: 565.72

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)(C)Oc1ccc(C[C@@H]2NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)CCCCNC(=O)CCNC2=O)cc1

Standard InChI:  InChI=1S/C31H43N5O5/c1-31(2,3)41-23-14-12-22(13-15-23)20-26-29(39)34-18-16-27(37)33-17-8-7-11-25(30(40)36-26)35-28(38)24(32)19-21-9-5-4-6-10-21/h4-6,9-10,12-15,24-26H,7-8,11,16-20,32H2,1-3H3,(H,33,37)(H,34,39)(H,35,38)(H,36,40)/t24-,25-,26-/m0/s1

Standard InChI Key:  IVBGSMWJTGJTBC-GSDHBNRESA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 565.72

Molecular Weight (Monoisotopic): 565.3264

AlogP: 1.75

#Rotatable Bonds: 7

Polar Surface Area: 151.65

Molecular Species: NEUTRAL

HBA: 6

HBD: 5

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 11.25

CX Basic pKa: 7.71

CX LogP: 1.60

CX LogD: 1.12

Aromatic Rings: 2

Heavy Atoms: 41

QED Weighted: 0.35

Np Likeness Score: 0.31

References

1. Haramura M, Okamachi A, Tsuzuki K, Yogo K, Ikuta M, Kozono T, Takanashi H, Murayama E..  (2002)  Design and synthesis of motilin antagonists derived from the [1-4] fragment of porcine motilin.,  45  (3): [PMID:11806718] [10.1021/jm010332u]

Source

Source(1):

• Scientific Literature